



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Modern Blood Culture Management Decisions and Method Options



Mark D. Gonzalez, PhD^a, Timothy Chao, MD, PhD^b,
Matthew A. Pettengill, PhD^{c,*}

KEYWORDS

• Blood culture • Bloodstream infections • Contamination • Sepsis

KEY POINTS

- Considerable improvements can be made in preanalytical aspects of blood culture collection that impact patient care.
- There are newer methods developed in recent years to improve time to reporting blood culture isolate identification and antibiotic susceptibility patterns.
- The successful utilization of rapid identification and antimicrobial susceptibility results requires coordination with antimicrobial stewardship programs.

INTRODUCTION

One of the most important functions of the clinical microbiology laboratory is the detection and characterization of organisms causing bloodstream infections. Several preanalytical considerations have a considerable impact on downstream results for blood cultures. The laboratory, with input from key stakeholders, selects blood culture media types and provides guidance on collection methods and collection site sterilization, the volume of blood to be collected, and downstream testing options for positive blood cultures. This article provides an update on recent data and developments in each of these areas.

SELECTION OF MEDIA AND ADDITIVE TYPES FOR BLOOD CULTURE

Most modern media formulations are similar, a base of soybean casein digest (trypticase soy broth) with sodium polyanethol sulfonate (SPS) as an anticoagulant. The

^a Microbiology, Section Director of Infectious Disease Serology, Children's Healthcare of Atlanta, 1405 Clifton Road, Northeast, Atlanta, GA 30322, USA; ^b Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, 132 South 10th Street, Room 285, Philadelphia, PA 19107, USA; ^c Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, 117 South 11th Street, Pavilion Building Suite 207, Philadelphia, PA 19107-4998, USA

* Corresponding author.

E-mail address: matthew.pettengill@jefferson.edu

Twitter: [@tim_hf_chao](https://twitter.com/tim_hf_chao) (T.C.)

headspace of the bottles consists of CO₂ and N₂ for anaerobic bottles and ambient air supplemented with CO₂ for aerobic bottles. Anaerobic bottles also include reducing agents. Two major decisions are whether to utilize bottles with polymeric resin beads to neutralize antibiotics, and if one's laboratory serves a pediatric population whether to use pediatric-specific bottles (aerobic only, modified media formulation, lower media volume, and lower SPS concentration). Resins can neutralize select antibacterial agents (including common empirically utilized antibiotics such as piperacillin-tazobactam, vancomycin, and some cephalosporins), but have lower to no ability to neutralize other agents (eg, carbapenems and fluoroquinolones).¹⁻³ Resins improve the yield of blood cultures for patients who are on antibiotics at the time of blood collection; this has clear advantages for initial blood cultures but also results in more positive cultures for patients subsequently on therapy, and thus more laboratory expense. The clinical significance of subsequent positive cultures in bottles with resins is unclear. Pediatric bottles have been compared with standard aerobic bottles *in vitro*,⁴ and also compared with aerobic and anaerobic bottles in clinical evaluations.⁵⁻⁷ Bloodstream infections in children are rarely caused by strict anaerobes. In the largest study to date that included aerobic and anaerobic culture in a pediatric population, only 15 of 723 clinically significant isolates (2.1%) were strict anaerobes isolated from anaerobic bottles.⁸ Bacteremia with strict aerobes may be more common in this population.⁹ This does not mean, however, that utilizing anaerobic bottles could not contribute to increased sensitivity for pediatric cultures. A more recent study demonstrated improved yield with 1 mL of blood divided evenly between aerobic (BACTEC Peds Plus/F) and anaerobic bottles (68/72, 94.4%) compared with 1 mL added to 1 pediatric bottle (56/72, 77.7%).⁵ The additionally detected organisms using the combination of aerobic and anaerobic bottles were mostly facultative anaerobes rather than strict anaerobes. Studies to date have either not specifically evaluated fastidious organisms (such as *Neisseria*) or are too small to expect a meaningful number of such isolates to occur in clinical evaluations; thus it is not clear if the modified media formulation or reduced SPS would offer advantages for these types of organisms in a larger study or clinical use. It seems that loading the entire volume into a pediatric bottle or dividing it evenly between a pediatric aerobic bottle and a standard anaerobic bottle are both reasonable and justifiable approaches to pediatric blood culture.

PREVENTING CONTAMINATION OF BLOOD CULTURES

Contamination of blood cultures has a big impact on patient care and hospital resources. Several key factors that can reduce contamination rates have been clearly demonstrated. Skin sites for collection should be disinfected with an alcohol-containing disinfectant, and blood should not be collected from an intravascular device unless specifically requested out of concern it is the source of bacteremia. Additionally, ongoing education should be provided to phlebotomy staff and other blood collectors, and methods or devices that divert an initial volume of blood can significantly reduce blood culture contamination rates.¹⁰⁻¹² In fact, it is possible to make so much progress relative to historic baselines that a group of experts on the topic recently proposed changing the longstanding performance standard for US health care institutions, currently set at less than 3% of blood cultures contaminated, with the proposal to consider lowering this expectation to less than 1% contamination.¹⁰ As noted, the use of commercial diversion devices reduced contamination rates,¹¹ which in models is projected to lead to considerable cost savings and reductions in patient length of stay.^{13,14} In 2 recent studies, blood culture contamination was

reduced without using expensive commercial diversion devices, by diverting a small amount of blood using vacutainer tubes by changing the test draw order, which could also be accomplished for blood cultures alone by simply discarding the diverted portion.^{15,16}

VOLUME OF BLOOD COLLECTED FOR CULTURE

The volume of blood collected for blood culture is the single most important variable in the ability of the microbiology laboratory to detect microorganisms causing bloodstream infections.^{17,18} The American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA) jointly recommend 2 to 4 collections per septic episode, with each collection consisting of 20 to 30 mL divided among 2 or 3 bottles.¹⁹ Thus, at a minimum, 40 mL total volume should be cultured per septic episode, with 2 important exceptions. The IDSA recommends that for neutropenic patients, blood collected for culture should be limited to 1% of total blood volume (usually approximately 70 mL/kg) in patients weighing less than 40 kg.²⁰ The other exception is pediatric patients, for whom there are various recommendations for blood culture volumes based on age or weight, with those from IDSA cited here.¹⁹ The volume of blood collected and number of bottles collected can be increased without increasing the number of collections by increasing the volume at each collection to 30 mL in 3 bottles (2 aerobic bottles and 1 anaerobic bottle in this study) instead of 20 mL, which could improve causative microorganism recovery without significantly increasing costs.²¹

Although blood collection happens outside of the laboratory, ensuring that adequate volume is collected is the direct responsibility of laboratory administration. The College of American Pathologists (CAP) requires that accredited laboratories have a system in place to evaluate adult blood culture volume and communicate these data at regular intervals to clinical staff responsible for blood collection. Laboratory-initiated education and quality improvement projects can lead to marked improvements in blood volume submitted. One group found that targeted education in intensive care units (ICUs) led to 30% to 60% sustained improvement in blood volume submitted on average.²² Another recent study found that a rigorous quality improvement program that included group education, targeted communications, and bottle marking led to not only considerably increased blood volume (increased from 2.3 mL average per bottle before implementation to 8.6 mL after implementation) but most importantly a 20% improved yield of true pathogens in blood culture.²³

BLOOD CULTURE SYSTEMS AND ALTERNATIVE BLOOD CULTURING METHODS

Numerous improvements in blood culture incubation and monitoring have occurred over time, culminating in the current continuous-monitoring blood culture system (CMBCS). Three US Food and Drug Administration (FDA)-cleared CMBCS are available, including BACTEC (Becton-Dickinson, Sparks, MD, USA), BacT/Alert (bioMérieux, Inc., Durham, North Carolina) and VersaTREK (Thermo Scientific, Waltham, Massachusetts). Key features are summarized in [Table 1](#). All 3 systems detect microbial growth via some form of gas detection but utilize distinct methods. Delays in getting bottles onto the CMBCS can result in delayed positive results or false-negative results. In a 30-month retrospective study of 50,955 blood cultures, where cultures were only loaded onto the CMBCS during the morning to late afternoon or otherwise held on the hospital floor at room temperature, 13.0% were positive while the laboratory was open, but only 10.8% were positive when the laboratory was closed.²⁴

Table 1
Summary of current continuous-monitoring blood culture system features

Blood Culture System	Method for Monitoring Growth	Bottle Types	Additional Information	FDA-Cleared Indications	Max Fill Volume
BacT/ALERT	Colorimetric change caused by drop in pH from increased CO ₂ levels	BacT/ALERT FA PLUS	Aerobic media with adsorbent polymeric resin beads	Blood or SBF	10 mL
		BacT/ALERT FN PLUS	Anaerobic media with adsorbent polymeric resin beads	Blood or SBF	10 mL
		BacT/ALERT PF PLUS	Pediatric, standard aerobic	Blood	4 mL
		BacT/ALERT SA	Standard aerobic	Blood or SBF	10 mL
		BacT/ALERT SN	Standard anaerobic	Blood or SBF	10 mL
		BacT/ALERT BPA	Aerobic media	Platelets	10 mL
		BacT/ALERT BPN	Anaerobic media	Platelets	10 mL
BACTEC	Change in fluorescence caused by a drop in pH from increased CO ₂ levels	BACTEC Plus Aerobic	Aerobic media with adsorbent polymeric resin beads	Blood	10 mL
		BACTEC Plus Anaerobic	Anaerobic media with adsorbent polymeric resin beads	Blood	10 mL
		BACTEC Peds Plus	Pediatric, aerobic media w/ adsorbent polymeric resin beads	Blood	5 mL
		BACTEC Lytic Anaerobic	Anaerobic media with detergent to lyse RBCs and WBCs	Blood	10 mL
		BACTEC Standard Aerobic	Standard aerobic	Blood	10 mL
		BACTEC Standard Anaerobic	Standard anaerobic	Blood	7 mL
		BACTEC Myco/F Lytic	Mycobacterial/fungal media	Blood	5 mL
VersaTREK	Measures pressure changes caused by gas consumption or production	REDOX 1	Aerobic	Blood or SBF	10 mL
		REDOX 2	Anaerobic	Blood or SBF	10 mL
		REDOX 1 EZ Draw	Aerobic, direct blood inoculation	Blood or SBF	5 mL
		REDOX 2 EZ Draw	Anaerobic, direct blood inoculation	Blood or SBF	5 mL
		VersaTREK Myco	Mycobacterial media	Blood, SBF or processed specimen	1 mL

Abbreviation: SBF, sterile body fluids.

The current BACTEC CMBCS model is the BACTEC FX, which is available in different sizes depending on the capacity required. Bottles for the BACTEC system contain fluorometric sensors that fluoresce in the presence of CO₂ via acidification. Specialized media (BACTEC Myco/F Lytic) for improved recovery of *Mycobacteria* and fungi are available.

The current BacT/Alert system models include the BacT/Alert 3D and the recently introduced BacT/Alert VIRTUO. Both systems detect CO₂ production via a colorimetric system present in the bottom of the bottles that changes color with pH. The BacT/ALERT VIRTUO system automates bottle loading and unloading, helping to maintain temperature stability. During the loading process, the instrument scans the bar-coded labels, determining the fill-level in the bottles, while on the instrument an improved algorithm shortens the time to positive detection. In 1 study comparing the BacT/ALERT VIRTUO with the BacT/ALERT 3D, 115 clinical isolates were inoculated into blood cultures, and although both systems demonstrated similar detection rates, the BacT/ALERT VIRTUO reduced time to detection by approximately 20%.²⁵ Similarly, a reduced time to detection was observed with BacT/ALERT VIRTUO in a multicenter study with clinical specimens, which was statistically significant for gram-negative bacilli and enterococci.²⁶ The type of BacT/ALERT bottle used determines the maximal volume inoculated. Additionally there are BacT/ALERT bottles FDA-cleared for sterile body fluids and platelet sterility testing (see [Table 1](#)).

Unlike the other CMBCS, microbial growth detection by the VersaTREK system requires an adapter to be affixed onto the bottles before instrument loading. This adapter allows the instrument to monitor pressure changes in CO₂, O₂, H₂, and N₂ caused by gas production or consumption by growing microorganisms. Additionally, the VersaTREK system is FDA-cleared for culturing mycobacteria from blood, processed specimens, and sterile body fluids, and for *Mycobacterium tuberculosis* susceptibility testing.

There are numerous studies comparing the CMBCS and media types. Recent examples will be highlighted. Overall, the CMBCS perform similarly in many aspects with some differences. One study compared the BacT/ALERT VIRTUO and BACTEC FX system using contrived bottles with differing (125 CFU/mL, 30 CFU/mL, and 5 CFU/mL) microorganism concentrations, for a total of 405 comparisons.²⁷ Although both systems flagged positive for all cultures at 125 CFU/mL and 30 CFU/mL, the BacT/ALERT VIRTUO demonstrated a lower false-negative rate (5.2%) at 5 CFU/mL compared with the BACTEC FX (8.1%), but no statistically significant difference was noted in the time to detection.²⁷ In contrast, another simulated study inoculated 2610 bottles with 30 CFU/mL of 330 clinical relevant species and compared the BacT/ALERT Virtuo, BacT/ALERT 3D and the BACTEC FX system. Although all 3 systems flagged positive for 99.6% of all cultures, the median time to positivity for the BacT/ALERT VIRTUO was significant shorter.²⁸ A previous study comparing the BacT/ALERT 3D and VersaTREK using patient specimens found no overall difference in time to positivity or isolation of microorganisms, but there was a higher false-positive rate with the VersaTREK system (ie, 1.6% vs 0.7% for aerobic bottles).²⁹ However, the VersaTREK demonstrated a statistically significant higher recovery of streptococci and enterococci.²⁹

As noted, monitoring and feedback to collectors of inadequate blood culture volumes is a CAP requirement, and the BacT/Alert and BACTEC can assist in volume determination. The BacT/Alert Virtuo scans the sample level to determine the inoculated volume. An evaluation of the BacT/Alert Virtuo volume monitoring of 1141 bottles was compared with weight-based volume determination.³⁰ Although the results between the BacT/Alert Virtuo and weight-based volume strongly correlated ($r = 0.87$),

the BacT/Alert Virtuo tended to overestimate volumes (median difference of 1.4 mL for the aerobic bottle and 0.2 mL for the anaerobic bottle). Software for the BACTEC FX, BD EpiCenter, determines the mean blood volume from at least 25 culture-negative aerobic bottles by measuring red blood cell metabolic activity. This measurement method means that low hematocrit levels and delays in getting bottles on the instrument can give inaccurate results. One study compared the BACTEC FX to weight-based volume determination, initially found that the BACTEC FX had a mean underestimation of 1.4 mL but this was reduced to a mean underestimation of 0.3 mL with a software upgrade.³¹ However, this improved software demonstrated a mean overestimation of 2.8 mL with plastic BACTEC bottles,³¹ but further updates were planned to adjust for plastic bottles.

In addition to the CMBCS, some laboratories use lysis centrifugation methods to culture blood for molds and mycobacteria. Note that CMBCS are the preferred method for recovery of *Candida* species and *Cryptococcus* species. In a 10-year retrospective study, the Isolator system recovered the lipid requiring *Malassezia* species and isolated dimorphic and filamentous fungi not recovered in CMBCS.³² However, this same study found that the Isolator rarely provided results not available by other methods, and there were many instances of fungal isolates deemed to be clinically significant.³²

INCUBATION TIME

Blood cultures are routinely incubated for 4 to 7 days with CMBCS. Studies indicate that 98% to 99% of true pathogens are detected within 5 days of incubation relative to longer incubation times.¹⁷ Five days of incubation appear to be optimal for balancing increased recovery versus occupying incubator space unnecessarily and delaying final reporting for negative cultures. It may be reasonable, however, to shorten incubation times to 4 days or even 3 days if equipment failure or a surge of demand for blood cultures (eg, during the COVID-19 pandemic) leads to a sudden demand for more CMBCS space than laboratory infrastructure can accommodate. Several studies demonstrated only modest reductions in true pathogen recovery with 3 to 4 days of incubation relative to longer times.^{33–35} Although routine incubation beyond 5 days is not necessary with CMBCS, even for HACEK organisms,³⁶ it may be justified to hold cultures for a longer period of time on request in select cases.

PROCESSING POSITIVE BLOOD CULTURES: STAINING METHODS AND IMPACT OF GRAM STAIN CALL TIME

The first analytical step in processing a positive blood culture is probably the most impactful step for patient care: the Gram stain. Studies have demonstrated that for therapeutic interventions, the reporting of Gram stain results to the patient care team was more impactful than reporting final antimicrobial susceptibility testing (AST) results.³⁷ The timing of Gram stain reporting matters too. In many clinical microbiology laboratories it can be difficult to provide highly skilled Gram stain readers on off shifts for rapid turnaround of positive blood culture Gram stains. Gram stain turn-around time for blood cultures was shown in a relatively small study to correlate with mortality, with increased mortality among patients with delayed Gram stain reporting.³⁸ Infrastructure can also be developed to allow for remote consultative review of blood culture Gram stains so that more experienced readers can assist technologists at remote laboratory sites if needed to improve accuracy.³⁹ Some microorganisms stain poorly or not at all with Gram reagents, and for positive blood cultures with negative Gram

stains there are alternative stains, such as acridine orange, which can be employed in addition to repeating Gram stains.

RAPID IDENTIFICATION FROM POSITIVE BLOOD CULTURES: MOLECULAR TESTING

There are several commercial, FDA-cleared, molecular tests available for the rapid identification (<2 hours) of organisms in positive blood culture bottles. These tests may target a single organism (eg, *Staphylococcus aureus*), or large panels of organisms tested simultaneously (gram-negative and gram-positive bacteria on the same test) or organized by Gram stain results “[Panels and Syndromic Testing in Clinical Microbiology](#)”. Molecular testing direct from blood culture bottles is sometimes negatively impacted by residual microbial nucleic acid in commercial blood culture media (sterile, but not always genetically inert), leading to false-positive results; this has led to product recalls for issues related to false-positive *Enterococcus* and *Proteus* identification in recent years. Blood culture molecular identification panels generally also include genetic markers of resistance for such targets as *mecA* when *Staphylococcus* is detected, *vanA/vanB* when *Enterococcus* is detected, and ESBL or carbapenemase genes such as KPC when gram-negative rods are detected “[Panels and Syndromic Testing in Clinical Microbiology](#)”.

RAPID IDENTIFICATION FROM POSITIVE BLOOD CULTURES: MASS SPECTROMETRY

Bacteria and yeast in positive blood culture bottles may also be directly identified using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS),^{40,41} a technology commonly employed for identification of bacteria and yeast colonies. Whereas colony growth can be tested directly, organisms in blood culture broth must be processed to separate the organism from blood cells for testing, and various methods have been evaluated.⁴² Identification accuracy for direct MALDI-TOF from blood culture bottles is typically better for gram-negative bacteria than for gram-positive bacteria, and can be improved by a short incubation on agar (smudge plate, 4–8 hours, 84%–97% with correct identification) prior to MALDI-TOF analysis.^{43,44}

RAPID, DIRECT, PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING OPTIONS

The Accelerate PhenoTestBC kit used in conjunction with the Accelerate Pheno system (APS) is the first FDA-cleared in vitro diagnostic test for pathogen identification and quantitative AST directly from positive blood cultures.⁴⁵ The APS uses multiplexed fluorescence in situ hybridization (FISH) to identify on-panel microbes based on the colocalization of target-specific probes with a universal bacterial probe in the same cell. The minimum inhibitory concentration (MIC) is calculated from analyzing the cellular morphokinetic growth pattern in the presence of antimicrobial agents. The APS assay can provide pathogen identity and quantitative AST phenotype within 2 and 7 hours, respectively. However, whether this rapid turnaround time (TAT) translates into more favorable clinical outcomes remains to be determined.^{46,47}

Studies using the APS assay have reported pathogen identification sensitivities ranging from 91.2% to 100% and specificities ranging from 97.3% to 100% for organisms on the panel.^{45,48–54} However, 1 study reported an overall false-positive rate as high as 9.5%, of which 42.1% is mitigated by having prior negative Gram stain.⁴⁵ Therefore, confirmatory Gram stain should be performed before performing the APS assay. AST results have demonstrated essential agreements (EAs) ranging from 94.5% to 97.6% and categorical agreements (CAs) ranging from 86% to 97.9% compared with routine methods. Importantly, lower CA values have been observed

for *Pseudomonas* species and *Acinetobacter* species.^{48,52,55} Because assay performance varies depending on the pathogen, laboratories should decide on which organisms to perform the APS assay to best complement existing techniques and improve resulting times. Although this assay has high sensitivity for target organisms, in 1 study only 58.1% to 88.7% of clinical samples analyzed by this assay received any pathogen identification.⁵⁶ This low overall sensitivity highlights the need to perform routine methods in parallel with the APS assay.

There is much interest in the application of FDA-approved automated AST platforms intended for use on isolated colonies, such as the BD Phoenix and Biomérieux VITEK2 systems, directly on positive blood culture samples. The Phoenix and VITEK 2 systems are capable of performing colorimetric-based biochemical identification and turbidimetric-based quantitative AST with TATs of 3 to 16 hours. Studies report variable performance of the Phoenix system depending on the species involved and the method of microbial extraction. For instance, the identity concordance of direct inoculation compared with standard procedure ranges from 82% with saponin-based to 92.9% to 95.2% with serum separation tube (SST)-based extraction methods.^{57–59} AST results using the Phoenix system similarly vary, with an overall CA of 77% and 95.4% to 99% when using saponin- and SST-based methods, respectively.^{57,58} Studies of direct phenotypic AST using the VITEK 2 system compared with standard techniques have similarly reported high identity concordance rates of 82.2% to 95.8% and AST CAs of 94.6% to 99.2% for gram-negative bacilli (GNB).^{60–63} Performance for gram-positive cocci (GPC) may not be as reliable.⁶⁰ However, parallel MALDI-TOF MS identification and VITEK 2 for AST can provide reasonably accurate results for GNB and GPC.^{64,65} Investigations comparing direct AST results using the VITEK 2 and Phoenix systems have also reported high CAs, ranging from 92.4% to 99.5%.^{66,67}

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recently published a rapid AST (RAST) method based on direct disk diffusion (dDD) testing of positive blood cultures on Mueller-Hinton (MH) or Mueller-Hinton Fastidious agar plates.⁶⁸ Zone diameter breakpoints after 4, 6, and 8 hours of incubation for 8 common bacterial species and relevant antibiotics are provided. Typical workflow begins with a Gram stain of positive blood culture, followed by inoculating the appropriate subculture plates and a RAST plate with the antibiotic disks of choice. Inhibition zone diameters after 4, 6, and 8 hours on the RAST plate can then be interpreted. In general, the EUCAST RAST method has CAs of greater than 90% when compared with standard method.^{68,69} Similarly, a Clinical and Laboratory Standards Institute (CLSI) committee has recently released some promising preliminary results.⁷⁰ Given their low costs and ease of use, standardized dDD methods may eventually allow more laboratories to perform direct phenotypic ASTs.

OTHER DIRECT ENZYME-BASED TARGETED ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS

Detection of bacterial antimicrobial resistance enzymatic activity is widely used for the qualitative phenotypic AST on isolated bacteria. Because these assays are relatively cheap and simple, many have explored their use directly on positive blood cultures to test for the presence of β -lactamase and/or carbapenemase-producing gram-negative bacteria, which are of great clinical concern internationally.^{71–74} Colorimetric methods usually start with microbial extraction from positive blood cultures using lysis centrifugation or a short subculture on solid media. The ideal choice of hemolytic agent varies depending on the assay. For example, 10% SDS is more compatible with the β -CARBA test, while 5% saponin is with the Carba NP and NeoRapid CARB tests.⁷³

Variations of CLSI's modified carbapenem inactivation method (mCIM) have also been used for bacteria with ESBL and carbapenemase activity directly from positive blood cultures.^{71,73,74} Briefly, bacteria are extracted from blood cultures and incubated with either a meropenem or a cephalosporin disk at 35°C to 37°C for approximately 2 hours. Zinc supplementation can be used for metallo- β -lactamase activity detection.⁷³ The impregnated disk is then applied on an MH plate that is inoculated either freshly or 2 hours previous with a 0.5 McFarland suspension of a standard antibiotic-susceptible strain. The inhibition zone is read and interpreted after 6 to 22 hours of incubation.

Overall, both colorimetric and mCIM-based methods demonstrate high specificities ($\geq 90\%$) and sensitivities (80%–100%) for the detection of β -lactamase and/or carbapenemase-producing *Enterobacterales* extracted directly from aerobic blood culture bottles.^{71–74} Resulting times between 20 minutes to 6.5 hours have been reported for colorimetric methods, and between 8 to 24 hours for mCIM-based methods. Although these early results are generally promising, more studies must be done to standardize methodology and result interpretation before clinical use.

STEWARDSHIP/UTILIZATION

By March of 2020, the US Centers for Medicare and Medicaid Services required all acute care hospitals to implement antimicrobial stewardship programs (ASPs).⁷⁵ ASPs ensure that patients receive appropriate antimicrobial regimens, which improves patient outcomes, reducing adverse events (eg, toxicity, antibiotic resistance, or *Clostridioides difficile* infection), and allows for optimal resource utilization. To meet these goals, the US Centers for Disease Control and Prevention recommend that ASPs work with the microbiology laboratory on diagnostic stewardship and implementation of rapid diagnostic testing (RDT).⁷⁶ In regards to blood cultures, the IDSA recommends that ASPs advocate for RDT from positive blood cultures to optimize therapy and improve outcomes.⁷⁷

Once blood cultures flag positive, it is through the use of RDTs, such as those described previously, that timely microorganism identification and potentially antimicrobial susceptibility/resistance information, via genotypic or phenotypic methods, can be quickly provided to clinicians. However, the impact of RDTs on patient outcomes requires ASP intervention. In a meta-analysis that included 31 observational studies (5920 patients) and various RDTs, it was found that RDTs had a mortality benefit but only in the presence of ASPs.⁷⁸ This mortality benefit was found with both gram-positive and gram-negative infections.⁷⁸ In addition to the mortality benefit of RDTs in combination with ASPs, this combination is also cost-effective. A cost-effectiveness evaluation of RDTs with or without ASPs was compared to conventional laboratory methods with ASP involvement.⁷⁹ It was found that the use of molecular RDTs with ASP had an 80% chance of being cost-effective, while it was only a 41.1% change without an ASP.⁷⁹ Thus it is imperative for laboratories to work with their ASPs to maximize the benefits of RDTs from positive blood cultures.

DISCLOSURE

The authors do not have any external funding or conflicts of interest.

REFERENCES

1. Chen IH, Nicolau DP, Kuti JL. Effect of clinically meaningful antibiotic concentrations on recovery of *Escherichia coli* and *Klebsiella pneumoniae* isolates from

- anaerobic blood culture bottles with and without antibiotic binding resins. *J Clin Microbiol* 2019;57(12):e01344.
2. Chen IH, Nicolau DP, Kuti JL. Recovery of gram-negative bacteria from aerobic blood culture bottles containing antibiotic binding resins after exposure to beta-lactam and fluoroquinolone concentrations. *J Clin Microbiol* 2019;57(10):e00849-19.
 3. Flayhart D, Borek AP, Wakefield T, et al. Comparison of BACTEC PLUS blood culture media to Bact/Alert FA blood culture media for detection of bacterial pathogens in samples containing therapeutic levels of antibiotics. *J Clin Microbiol* 2007;45(3):816-21.
 4. Lancaster DP, Friedman DF, Chiotos K, et al. Blood volume required for detection of low levels and ultralow levels of organisms responsible for neonatal bacteremia by use of bactec peds plus/F, Plus Aerobic/F Medium, and the BD Bactec FX System: an in Vitro Study. *J Clin Microbiol* 2015;53(11):3609-13.
 5. Yaacobi N, Bar-Meir M, Shchors I, et al. A prospective controlled trial of the optimal volume for neonatal blood cultures. *Pediatr Infect Dis J* 2015;34(4):351-4.
 6. Messbarger N, Neemann K. Role of anaerobic blood cultures in neonatal bacteremia. *J Pediatric Infect Dis Soc* 2018;7(3):e65-9.
 7. Gross I, Gordon O, Abu Ahmad W, et al. Yield of anaerobic blood cultures in pediatric emergency department patients. *Pediatr Infect Dis J* 2018;37(4):281-6.
 8. Zaidi AK, Knaut AL, Mirrett S, et al. Value of routine anaerobic blood cultures for pediatric patients. *J Pediatr* 1995;127(2):263-8.
 9. Dien Bard J, McElvania TeKippe E. Diagnosis of bloodstream infections in children. *J Clin Microbiol* 2016;54(6):1418-24.
 10. Doern GV, Carroll KC, Diekema DJ, et al. A comprehensive update on the problem of blood culture contamination and a discussion of methods for addressing the problem. *Clin Microbiol Rev* 2019;33(1):e00009-19.
 11. Rupp ME, Cavalieri RJ, Marolf C, et al. Reduction in blood culture contamination through use of initial specimen diversion device. *Clin Infect Dis* 2017;65(2):201-5.
 12. Weinstein MP. Blood culture contamination: persisting problems and partial progress. *J Clin Microbiol* 2003;41(6):2275-8.
 13. Skoglund E, Dempsey CJ, Chen H, et al. Estimated clinical and economic impact through use of a novel blood collection device to reduce blood culture contamination in the emergency department: a cost-benefit analysis. *J Clin Microbiol* 2019;57(1):e01015-18.
 14. Geisler BP, Jilg N, Patton RG, et al. Model to evaluate the impact of hospital-based interventions targeting false-positive blood cultures on economic and clinical outcomes. *J Hosp Infect* 2019;102(4):438-44.
 15. Lalezari A, Cohen MJ, Svinik O, et al. A simplified blood culture sampling protocol for reducing contamination and costs: a randomized controlled trial. *Clin Microbiol Infect* 2020;26(4):470-4.
 16. Zimmerman FS, Karamah H, Ben-Chetrit E, et al. Modification of blood test draw order to reduce blood culture contamination: a randomized clinical trial. *Clin Infect Dis* 2019. <https://doi.org/10.1093/cid/ciz971>.
 17. Cockerill FR 3rd, Wilson JW, Vetter EA, et al. Optimal testing parameters for blood cultures. *Clin Infect Dis* 2004;38(12):1724-30.
 18. Mermel LA, Maki DG. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. *Ann Intern Med* 1993;119(4):270-2.
 19. Miller JM, Binnicker MJ, Campbell S, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the

- Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018;67(6):813–6.
20. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011;52(4):e56–93.
 21. Patel R, Vetter EA, Harmsen WS, et al. Optimized pathogen detection with 30-compared to 20-milliliter blood culture draws. J Clin Microbiol 2011;49(12):4047–51.
 22. Zaleski M, Erdman P, Adams J, et al. Establishing a long-term model for analysis and improvement of underfilled blood culture volumes. Am J Clin Pathol 2019; 151(2):164–70.
 23. Khare R, Kothari T, Castagnaro J, et al. Active monitoring and feedback to improve blood culture fill volumes and positivity across a large integrated health system. Clin Infect Dis 2020;70(2):262–8.
 24. Venturelli C, Righi E, Borsari L, et al. Impact of pre-analytical time on the recovery of pathogens from blood cultures: results from a large retrospective survey. PLoS One 2017;12(1):e0169466.
 25. Altun O, Almuhayawi M, Luthje P, et al. Controlled evaluation of the new BacT/alert virtuo blood culture system for detection and time to detection of bacteria and yeasts. J Clin Microbiol 2016;54(4):1148–51.
 26. Jacobs MR, Mazzulli T, Hazen KC, et al. Multicenter clinical evaluation of BacT/alert virtuo blood culture system. J Clin Microbiol 2017;55(8):2413–21.
 27. Park J, Han S, Shin S. Comparison of growth performance of the BacT/ALERT VIRTUO and BACTEC FX blood culture systems under simulated bloodstream infection conditions. Clin Lab 2017;63(1):39–46.
 28. Menchinelli G, Liotti FM, Fiori B, et al. In vitro Evaluation of BACT/ALERT(R) VIRTUO(R), BACT/ALERT 3D(R), and BACTEC FX automated blood culture systems for detection of microbial pathogens using simulated human blood samples. Front Microbiol 2019;10:221.
 29. Mirrett S, Hanson KE, Reller LB. Controlled clinical comparison of VersaTREK and BacT/ALERT blood culture systems. J Clin Microbiol 2007;45(2):299–302.
 30. Lee S, Kim S. Accuracy of BacT/alert virtuo for measuring blood volume for blood culture. Ann Lab Med 2019;39(6):590–2.
 31. Coorevits L, Van den Abeele AM. Evaluation of the BD BACTEC FX blood volume monitoring system as a continuous quality improvement measure. Eur J Clin Microbiol Infect Dis 2015;34(7):1459–66.
 32. Campigotto A, Richardson SE, Sebert M, et al. Low utility of pediatric isolator blood culture system for detection of fungemia in children: a 10-year review. J Clin Microbiol 2016;54(9):2284–7.
 33. Bourbeau PP, Foltzer M. Routine incubation of BacT/ALERT FA and FN blood culture bottles for more than 3 days may not be necessary. J Clin Microbiol 2005; 43(5):2506–9.
 34. Bourbeau PP, Pohlman JK. Three days of incubation may be sufficient for routine blood cultures with BacT/Alert FAN blood culture bottles. J Clin Microbiol 2001; 39(6):2079–82.
 35. Wilson ML, Mirrett S, Reller LB, et al. Recovery of clinically important microorganisms from the BacT/Alert blood culture system does not require testing for seven days. Diagn Microbiol Infect Dis 1993;16(1):31–4.
 36. Petti CA, Bhally HS, Weinstein MP, et al. Utility of extended blood culture incubation for isolation of *Haemophilus*, *Actinobacillus*, *Cardiobacterium*, *Eikenella*, and

- Kingella* organisms: a retrospective multicenter evaluation. J Clin Microbiol 2006; 44(1):257–9.
37. Munson EL, Diekema DJ, Beekmann SE, et al. Detection and treatment of blood-stream infection: laboratory reporting and antimicrobial management. J Clin Microbiol 2003;41(1):495–7.
 38. Barenfanger J, Graham DR, Kolluri L, et al. Decreased mortality associated with prompt Gram staining of blood cultures. Am J Clin Pathol 2008;130(6):870–6.
 39. Martinez RM. Remote technical review of blood culture gram stains at a large integrated healthcare network. J Appl Lab Med 2019;3(4):733–4.
 40. Spanu T, Posteraro B, Fiori B, et al. Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of *Candida* species causing blood-stream infections: an observational study in two large microbiology laboratories. J Clin Microbiol 2012;50(1):176–9.
 41. Lagace-Wiens PR, Adam HJ, Karlowsky JA, et al. Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry and a commercial extraction system: analysis of performance, cost, and turnaround time. J Clin Microbiol 2012;50(10):3324–8.
 42. Saffert RT, Cunningham SA, Mandrekar J, et al. Comparison of three preparatory methods for detection of bacteremia by MALDI-TOF mass spectrometry. Diagn Microbiol Infect Dis 2012;73(1):21–6.
 43. Chen Y, Porter V, Mubareka S, et al. Rapid identification of bacteria directly from positive blood cultures by use of a serum separator tube, smudge plate preparation, and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2015;53(10):3349–52.
 44. Mitchell SL, Alby K. Performance of microbial identification by MALDI-TOF MS and susceptibility testing by VITEK 2 from positive blood cultures after minimal incubation on solid media. Eur J Clin Microbiol Infect Dis 2017;36(11):2201–6.
 45. Pancholi P, Carroll KC, Buchan BW, et al. Multicenter evaluation of the Accelerate PhenoTest BC Kit for rapid identification and phenotypic antimicrobial susceptibility testing using morphokinetic cellular analysis. J Clin Microbiol 2018;56(4). e01329-17.
 46. Ehren K, Meissner A, Jazmati N, et al. Clinical impact of rapid species identification from positive blood cultures with same-day phenotypic antimicrobial susceptibility testing on the management and outcome of bloodstream infections. Clin Infect Dis 2020;70(7):1285–93.
 47. Juttukonda LJ, Katz S, Gillon J, et al. Impact of a rapid blood culture diagnostic test in a children’s hospital depends on gram-positive versus gram-negative organism and day versus night shift. J Clin Microbiol 2020;58(4). e01400-19.
 48. Bowler SL, Towne JW, Humphries RM, et al. Evaluation of the accelerate pheno system for identification of *Acinetobacter* clinical isolates and minocycline susceptibility testing. J Clin Microbiol 2019;57(3). e01711-18.
 49. Burnham JP, Wallace MA, Fuller BM, et al. Clinical effect of expedited pathogen identification and susceptibility testing for gram-negative bacteremia and candidemia by use of the accelerate pheno(TM) System. J Appl Lab Med 2019;3(4): 569–79.
 50. Charnot-Katsikas A, Tesic V, Love N, et al. Use of the accelerate pheno system for identification and antimicrobial susceptibility testing of pathogens in positive blood cultures and impact on time to results and workflow. J Clin Microbiol 2018;56(1). e01166-17.

51. De Angelis G, Grossi A, Menchinelli G, et al. Rapid molecular tests for detection of antimicrobial resistance determinants in gram-negative organisms from positive blood cultures: a systematic review and meta-analysis. *Clin Microbiol Infect* 2020;26(3):271–80.
52. Descours G, Desmurs L, Hoang TLT, et al. Evaluation of the Accelerate Pheno system for rapid identification and antimicrobial susceptibility testing of Gram-negative bacteria in bloodstream infections. *Eur J Clin Microbiol Infect Dis* 2018;37(8):1573–83.
53. Lutgring JD, Bittencourt C, McElvania TeKippe E, et al. Evaluation of the accelerate pheno system: results from two academic medical centers. *J Clin Microbiol* 2018;56(4). e01672-17.
54. Schneider JG, Wood JB, Smith NW, et al. Direct antimicrobial susceptibility testing of positive blood cultures: a comparison of the Accelerate Pheno and VITEK(R) 2 systems. *Diagn Microbiol Infect Dis* 2019;95(3):114841.
55. Calderaro A, Buttrini M, Martinelli M, et al. Rapid microbial identification and phenotypic antimicrobial susceptibility testing directly from positive blood cultures: a new platform compared to routine laboratory methods. *Diagn Microbiol Infect Dis* 2020;96(3):114955.
56. Trotter AJ, Aydin A, Strinden MJ, et al. Recent and emerging technologies for the rapid diagnosis of infection and antimicrobial resistance. *Curr Opin Microbiol* 2019;51:39–45.
57. Lupetti A, Barnini S, Castagna B, et al. Rapid identification and antimicrobial susceptibility profiling of gram-positive cocci in blood cultures with the Vitek 2 system. *Eur J Clin Microbiol Infect Dis* 2010;29(1):89–95.
58. Beuving J, Verbon A, Gronthoud FA, et al. Antibiotic susceptibility testing of grown blood cultures by combining culture and real-time polymerase chain reaction is rapid and effective. *PLoS One* 2011;6(12):e27689.
59. Funke G, Funke-Kissling P. Use of the BD PHOENIX Automated Microbiology System for direct identification and susceptibility testing of gram-negative rods from positive blood cultures in a three-phase trial. *J Clin Microbiol* 2004;42(4):1466–70.
60. Chen JR, Lee SY, Yang BH, et al. Rapid identification and susceptibility testing using the VITEK 2 system using culture fluids from positive BacT/ALERT blood cultures. *J Microbiol Immunol Infect* 2008;41(3):259–64.
61. Munoz-Davila MJ, Yague G, Albert M, et al. Comparative evaluation of Vitek 2 identification and susceptibility testing of gram-negative rods directly and isolated from BacT/ALERT-positive blood culture bottles. *Eur J Clin Microbiol Infect Dis* 2012;31(5):663–9.
62. Bruins MJ, Bloembergen P, Ruijs GJ, et al. Identification and susceptibility testing of Enterobacteriaceae and *Pseudomonas aeruginosa* by direct inoculation from positive BACTEC blood culture bottles into Vitek 2. *J Clin Microbiol* 2004;42(1):7–11.
63. Ling TK, Liu ZK, Cheng AF. Evaluation of the VITEK 2 system for rapid direct identification and susceptibility testing of gram-negative bacilli from positive blood cultures. *J Clin Microbiol* 2003;41(10):4705–7.
64. Romero-Gomez MP, Gomez-Gil R, Pano-Pardo JR, et al. Identification and susceptibility testing of microorganism by direct inoculation from positive blood culture bottles by combining MALDI-TOF and Vitek-2 Compact is rapid and effective. *J Infect* 2012;65(6):513–20.
65. De Angelis G, Posteraro B, Menchinelli G, et al. Antimicrobial susceptibility testing of pathogens isolated from blood culture: a performance comparison of

- Accelerate Pheno and VITEK(R) 2 systems with the broth microdilution method. *J Antimicrob Chemother* 2019;74(Suppl 1):i24–31.
66. Gherardi G, Angeletti S, Panitti M, et al. Comparative evaluation of the Vitek-2 Compact and Phoenix systems for rapid identification and antibiotic susceptibility testing directly from blood cultures of gram-negative and gram-positive isolates. *Diagn Microbiol Infect Dis* 2012;72(1):20–31.
 67. Horing S, Massarani AS, Loffler B, et al. Rapid antibiotic susceptibility testing in blood culture diagnostics performed by direct inoculation using the VITEK(R)-2 and BD Phoenix platforms. *Eur J Clin Microbiol Infect Dis* 2019;38(3):471–8.
 68. Jonasson E, Matuschek E, Kahlmeter G. The EUCAST rapid disc diffusion method for antimicrobial susceptibility testing directly from positive blood culture bottles. *J Antimicrob Chemother* 2020;75(4):968–78.
 69. Jasuja JK, Zimmermann S, Burckhardt I. Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for positive blood cultures in clinical practice using a total lab automation. *Eur J Clin Microbiol Infect Dis* 2020;39(7):1305–13.
 70. Chandrasekaran S, Abbott A, Campeau S, et al. Direct-from-blood-culture disk diffusion to determine antimicrobial susceptibility of gram-negative bacteria: preliminary report from the clinical and laboratory standards institute methods development and standardization working group. *J Clin Microbiol* 2018;56(3). e01678-17.
 71. Bianco G, Boattini M, Iannaccone M, et al. Direct beta-lactam inactivation method: a new low-cost assay for rapid detection of carbapenemase- or extended-spectrum-beta-lactamase-producing *Enterobacterales* directly from positive blood culture bottles. *J Clin Microbiol* 2019;58(1). e01178-19.
 72. Lima-Morales D, Avila H, Soldi T, et al. Rapid detection of carbapenemase production directly from blood culture by colorimetric methods: evaluation in a routine microbiology laboratory. *J Clin Microbiol* 2018;56(9). e00325-18.
 73. Meier M, Hamprecht A. Rapid detection of carbapenemases directly from positive blood cultures by the beta-CARBA test. *Eur J Clin Microbiol Infect Dis* 2019;38(2):259–64.
 74. Sfeir MM, Satlin MJ, Fauntleroy KA, et al. Blood-modified carbapenem inactivation method: a phenotypic method for detecting carbapenemase-producing *Enterobacteriaceae* directly from positive blood culture broths. *J Clin Microbiol* 2020;58(2). e01377-19.
 75. Federal_Register. Medicare and Medicaid programs; regulatory provisions to promote program efficiency, transparency, and burden reduction; fire safety requirements for certain dialysis facilities; hospital and critical access hospital (CAH) changes to promote innovation, flexibility, and improvement in patient care. *Fed Regist* 2019;84:51732–834.
 76. CDC. The Core Elements of Hospital Antibiotic Stewardship Programs: 2019. 2019. Available at: <https://www.cdc.gov/antibiotic-use/core-elements/hospital.html>.
 77. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the society for Healthcare Epidemiology of America. *Clin Infect Dis* 2016;62(10):e51–77.
 78. Timbrook TT, Morton JB, McConeghy KW, et al. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. *Clin Infect Dis* 2017;64(1):15–23.
 79. Pliakos EE, Andreatos N, Shehadeh F, et al. The cost-effectiveness of rapid diagnostic testing for the diagnosis of bloodstream infections with or without antimicrobial stewardship. *Clin Microbiol Rev* 2018;31(3). e00095-17.